GLP-1 receptor agonists, alone or in combination with GIP and/or glucagon receptor agonists, represent promising, effective pharmacotherapies for the treatment of MASLD/MASH. Larger and longer-duration clinical trials are needed to further evaluate the efficacy and safety of GIP receptor and glucagon receptor agonism.
No takes yet. Share an insight, caveat, or question.
Zafer et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: